Hydrocortisone Roussel

Hydrocortisone Roussel is an oral corticosteroid medication whose active ingredient is hydrocortisone. It is supplied in a tablet (or oral) form, with the specific strength not disclosed in the available data. As a glucocorticoid, it belongs to the anti‑inflammatory and immunosuppressant therapeutic class and is marketed within the European Union. The product is used under medical supervision for conditions requiring glucocorticoid replacement or anti‑inflammatory therapy.

Hydrocortisone Roussel is prescribed for several clinical situations where glucocorticoid activity is required.

- Primary adrenal insufficiency (Addison’s disease) and other forms of adrenal hormone deficiency. - Replacement therapy during periods of physiological stress such as surgery or severe illness. - Management of acute inflammatory episodes in autoimmune disorders, for example systemic lupus erythematosus or rheumatoid arthritis. - Short‑term control of severe allergic reactions or skin inflammation when other treatments are insufficient.

Adverse reactions to Hydrocortisone Roussel can vary in frequency and severity.

Common: - Increased appetite, weight gain, or fluid retention. - Elevated blood pressure or mild edema. - Mood changes such as irritability or insomnia. - Gastrointestinal discomfort, including nausea or dyspepsia. - Skin thinning or easy bruising.

Serious: - Severe hyperglycemia or new‑onset diabetes mellitus. - Suppression of the hypothalamic‑pituitary‑adrenal axis leading to adrenal crisis on abrupt withdrawal. - Opportunistic infections, including fungal or viral reactivation. - Osteoporosis or increased risk of fractures with long‑term use. - Psychiatric disturbances such as depression or psychosis.

When prescribing Hydrocortisone Roussel, clinicians consider several precautionary measures to minimize risk.

- Assess baseline blood glucose, blood pressure, and electrolyte status before initiating therapy. - Use the lowest effective dose for the shortest duration required to achieve therapeutic goals. - Monitor for signs of infection, especially in immunocompromised patients. - Taper gradually when discontinuing long‑term treatment to avoid adrenal insufficiency. - Avoid use in patients with known hypersensitivity to hydrocortisone or formulation excipients. - Consider bone density evaluation for patients expected to receive prolonged therapy.

Hydrocortisone Roussel may interact with other medicines, influencing its efficacy or safety profile.

Avoid: - Strong CYP3A4 inducers such as rifampin, carbamazepine, or phenytoin, which can reduce hydrocortisone concentrations. - Concurrent use of systemic antifungal agents like ketoconazole that increase glucocorticoid levels and risk of toxicity.

Use with caution: - Non‑steroidal anti‑inflammatory drugs (NSAIDs) that may heighten the risk of gastrointestinal bleeding. - Anticoagulants (e.g., warfarin) because glucocorticoids can alter coagulation parameters. - Diabetic medications, as hydrocortisone may raise blood glucose and require dose adjustments. - Vaccines, particularly live attenuated vaccines, due to potential immunosuppression. - Antihypertensive agents, because fluid retention may counteract blood pressure control.